Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America by Cesar, Carina et al.
Health outcomes among HIV-positive
Latinos initiating antiretroviral
therapy in North America versus
Central and South America
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Cesar, C., J. R. Koethe, M. J. Giganti, P. Rebeiro, K. N. Althoff, S.
Napravnik, A. Mayor, et al. 2016. “Health outcomes among HIV-
positive Latinos initiating antiretroviral therapy in North America
versus Central and South America.” Journal of the International




Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions




Health outcomes among HIV-positive Latinos initiating
antiretroviral therapy in North America versus Central
and South America
Carina Cesar§,*,1, John R Koethe*,2, Mark J Giganti3, Peter Rebeiro2, Keri N Althoff4, Sonia Napravnik5,
Angel Mayor6, Beatriz Grinsztejn7, Marcelo Wolff8, Denis Padgett9, Juan Sierra-Madero10, Eduardo Gotuzzo11,
Timothy R Sterling2, James Willig12, Julie Levison13, Mari Kitahata14, Maria C Rodriguez-Barradas15,
Richard D Moore16, Catherine McGowan2, Bryan E Shepherd3, Pedro Cahn1, for the Caribbean, Central and
South America Network for HIV epidemiology (CCASAnet) and the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD)1
§Corresponding author: Carina Cesar, Peluffo 3932, Buenos Aires, C1202ABB, Argentina. Tel: +54 11 4981 7777 (Ext. 114). (carina.cesar@huesped.org.ar)
*These authors have contributed equally to the work.
Abstract
Introduction: Latinos living with HIV in the Americas share a common ethnic and cultural heritage. In North America, Latinos
have a relatively high rate of new HIV infections but lower rates of engagement at all stages of the care continuum, whereas in
Latin America antiretroviral therapy (ART) services continue to expand to meet treatment needs. In this analysis, we compare
HIV treatment outcomes between Latinos receiving ART in North America versus Latin America.
Methods: HIV-positive adults initiating ART at Caribbean, Central and South America Network for HIV (CCASAnet) sites were
compared to Latino patients (based on country of origin or ethnic identity) starting treatment at North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD) sites in the United States and Canada between 2000 and 2011. Cox
proportional hazards models compared mortality, treatment interruption, antiretroviral regimen change, virologic failure and
loss to follow-up between cohorts.
Results: The study included 8400 CCASAnet and 2786 NA-ACCORD patients initiating ART. CCASAnet patients were younger
(median 35 vs. 37 years), more likely to be female (27% vs. 20%) and had lower nadir CD4 count (median 148 vs. 195 cells/mL,
pB0.001 for all). In multivariable analyses, CCASAnet patients had a higher risk of mortality after ART initiation (adjusted hazard
ratio (AHR) 1.61; 95% confidence interval (CI): 1.32 to 1.96), particularly during the first year, but a lower hazard of treatment
interruption (AHR: 0.46; 95% CI: 0.42 to 0.50), change to second-line ART (AHR: 0.56; 95% CI: 0.51 to 0.62) and virologic failure
(AHR: 0.52; 95% CI: 0.48 to 0.57).
Conclusions: HIV-positive Latinos initiating ART in Latin America have greater continuity of treatment but are at higher risk of
death than Latinos in North America. Factors underlying these differences, such as HIV testing, linkage and access to care,
warrant further investigation.
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Introduction
In 2012, the World Health Organization (WHO) estimated
there were 1.3 million HIV-positive individuals in the United
States and Canada and 1.5 million in the countries of Latin
America (including Mexico) [1]. In the United States, over
16% of individuals self-identified as Hispanic or Latino in the
2010 US census (defined as persons of Cuban, Mexican,
Puerto Rican, South or Central American or other Spanish
culture or origin regardless of race). Latinos in the United
States have a rate of new HIV infections approximately three
times greater than among non-Hispanic whites, but lower
rates of engagement at all stages of the care continuum [24].
US Latinos are also more likely to be diagnosed with HIV at
later disease stages, and disparities in obtaining medical care
can be exacerbated by a lack of insurance, linguistic barriers,
stigma and differences in patient-provider communication
[58].
For HIV-positive Latinos in Mexico, Central America and
South America, the availability of HIV care and antiretroviral
therapy (ART) has expanded rapidly over the past decade,
with approximately 75% of the estimated 790,000 persons in
need of ART able to access treatment [1]. Latin America has
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diverse economic and social contexts, and prior studies have
found that mortality and programme retention vary con-
siderably between countries [912]. A recent analysis of six
Latin American countries and one Caribbean country found
that the overall mortality rate after five years of ART,
estimated to be 10%, was generally lower than that observed
in sub-Saharan Africa, but higher than that in Europe and
North America [1216], although rates were heterogeneous
between countries.
The goal of this study was to estimate regional differences
in clinical characteristics at ART initiation, mortality, ART
discontinuation or changes and virologic failure among HIV-
positive Latinos in the Americas. We compared outcomes of
HIV-positive Latino patients initiating ART in Canada and the
United States (hereafter referred to as North America) to
those in patients in six Latin American countries (Argentina,
Brazil, Chile, Honduras, Mexico and Peru) using the regional
databases of the International Epidemiologic Databases to
Evaluate AIDS (IeDEA) network.
Methods
Participants and settings
Patient-level HIV treatment and care data were aggregated
from two multinational regional consortia of IeDEA: the
Caribbean, Central and South America Network for HIV
research (CCASAnet) and the North American AIDS Cohort
Collaboration on Research and Design (NA-ACCORD). These
consortia have been profiled elsewhere [17,18].
Briefly, CCASAnet is a network of clinical sites in seven
diverse Caribbean, Central and South American countries
that pools data collected as part of HIV treatment and care
programmes. In this study, we included data from eight
CCASAnet sites in six countries: Hospital Ferna´ndez and
Centro Me´dico Hue´sped in Buenos Aires, Argentina (HF/
CMH-Argentina); Instituto Nacional de Infectologia Evandro
Chagas in Rio de Janeiro, Brazil (INI-Brazil); Fundacio´n Arriara´n
in Santiago, Chile (FA-Chile); Instituto Honduren˜o de Seguri-
dad Social and Hospital de Especialidades in Tegucigalpa,
Honduras (IHSS/HE-Honduras); Instituto Nacional de Ciencias
Me´dicas y Nutricio´n Salvador Zubira´n in Mexico City, Mexico
(INNSZ-Mexico); and Instituto de Medicina Tropical Alexander
von Humboldt in Lima, Peru (IMTAvH-Peru). The CCASAnet
site in Haiti was not included, given Haiti’s African ethnic
ancestry and non-Hispanic cultural heritage.
NA-ACCORD includes ]200 sites in 25 single and multisite
cohorts throughout the United States and Canada. In this
study, data from 11 NA-ACCORD clinical cohorts were
included: Fenway Community Health Center (Boston, MA),
HIV Research Network, Johns Hopkins HIV Clinical Cohort
(Baltimore, MD), Montreal Chest Institute Immunodeficiency
Service Cohort, Ontario HIV Treatment Network Cohort
Study, Retrovirus Research Center, Southern Alberta Clinic
Cohort, Study of the Consequences of the Protease Inhibitor
Era, University of Alabama at Birmingham 1917 Clinic Cohort,
University of Washington HIV Cohort and Vanderbilt-Meharry
Centers for AIDS Research (CFAR) Cohort. These sites
included patients from 17 US states, Puerto Rico, and 4
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Countries with <100 Persons Contributing are Hatched
Figure 1. Geographic distribution of NA-ACCORD and CCASAnet patients included in the analysis cohort.
Cesar C et al. Journal of the International AIDS Society 2016, 19:20684
http://www.jiasociety.org/index.php/jias/article/view/20684 | http://dx.doi.org/10.7448/IAS.19.1.20684
2
Canadian provinces (Figure 1). Latinos in NA-ACCORD were
identified based on either self-reported Hispanic ethnicity or
self-reported country of birth in South America, Central
America, Spanish-speaking countries in the Caribbean or
Mexico. The NA-ACCORD cohorts not included in the analysis
either did not have patients with Hispanic ethnicity or
declined to provide data.
Our analysis cohort was restricted to ART-naive adult HIV-
positive patients initiating ART between 2000 and 2011.
Patients with an undetectable HIV-1 RNA viral load (VL) prior
to reported date of ART initiation were excluded. Outcomes
wereassessedusingdata collected through31December 2011.
Clinical and epidemiological data were collected at each
centre, de-identified and sent to the Data Coordinating Center
at Vanderbilt University, USA. Institutional ethics review
boards from all sites and Vanderbilt approved the project,
waiving the requirement for individual patient informed
consent.
Outcomes
The time from ART initiation to each of five long-term
outcomes was assessed: all-cause mortality, treatment inter-
ruption, major treatment change, virologic failure and loss
to follow-up. ART was defined as a combination of three
antiretroviral agents from at least two classes, or a triple
nucleoside/nucleotide reverse transcriptase inhibitor regimen
containing abacavir or tenofovir. Patients without an event
were censored at 31 December 2011 or the date of their last
clinical, pharmacy or laboratory visit, whichever occurred first.
Participant deaths in NA-ACCORD are recorded by the
individual cohorts when the death can be confirmed, and
deaths among patients lost to care are ascertained using
routine surveillance andmatching of US national and Canadian
provincial death indexes. In CCASAnet, methods to ascertain
death differ across sites. At IHSS/HE-Honduras, deaths are
recorded after field workers contact patient family members
following a missed visit. At all other sites, deaths occurring at
affiliated hospitals or other clinical sites are recorded, as are
notifications of deaths by relatives of patients. Additionally,
study staff at INI-Brazil, FA-Chile, INNSZ-Mexico and IMTAvH-
Peru sites query government death registry databases for
patients lost to care at least annually.
Treatment interruption was defined as an interruption
of the initial ART regimen for 14 days. Major treatment
change included switching to a ‘‘second-line’’ regimen, defi-
ned as (1) a change to a boosted protease inhibitor (PI)-based
regimen; (2) switching to a different PI if a patient’s first
regimen included a boosted PI; (3) switching to a ‘‘third-line’’
drug (darunavir, tipranavir, etravirine, enfuvirtide, maraviroc or
raltegravir); or (4) changing to non-nucleoside reverse tran-
scriptase inhibitor (NNRTI), boosted PI or switching, deleting or
adding a third-line drug for those patients who had started
treatment on a third-line drug. Virologic failure was defined as
at least one of the following: (1) VL 400 copies/mL after six
months of therapy, (2) VL B400 copies/mL followed by a
single value 1000 copies/mL or (3) VL B400 copies/mL
followed by two consecutive VL 400 copies/mL. The
threshold of 400 copies/mLwas chosen based on the detection
limit for assays used at many of the sites during the study
period. Patients who did not have a VLmeasurement after ART
initiation were excluded from the virologic failure analyses.
Patients who had a gap between VL measurements of greater
than one year were censored at the last measurement prior to
the gap. Loss to follow-up (LFU) was defined as lack of
information about the patient within 180 days prior to the
database closing date; for patients lost to follow-up, the date of
LFU was defined as date of their last visit.
Statistical analysis
Univariate comparisons were performed using Wilcoxon
rank sum and chi-square tests. Kaplan-Meier estimates and
corresponding confidence intervals (CIs) of the probability of
mortality were calculated for each consortium.The cumulative
incidence and corresponding 95% CI of treatment interrup-
tion, ART regimen change and virologic failure were also
estimated and these models accounted for mortality as a
competing risk. Separate multivariable Cox proportional
hazards models were fit to compare the hazard of death,
major treatment modification and treatment failure between
patients in CCASAnet and NA-ACCORD. All multivariable
models were adjusted for age, sex, reported mode of
transmission, nadir CD4 T-cell count (CD4 count) and clinical
AIDS prior to treatment initiation, initial ART regimen and
year of ART initiation. Restricted cubic splines were used for
continuous variables to account for non-linear trends [19].
Multiple imputation was implemented to impute missing
covariate values [20].
Different frequencies of VL measurement between cohorts
may have biased the results since patients with more VL
measurements had more opportunities to be classified as a
treatment failure. We thus compared the incidence of a
detectable VL greater than six months after ART initiation
while accounting for the number of VL measurements using
a multivariable negative binomial regression model. We
report the adjusted relative proportions of detectable VL
per measurement and corresponding 95% CI.
Brazilian HIV treatment sites contributing data to CCASA-
net were included in the primary analysis, as were Brazilian
patients living in the United States or Canada and enrolled in
NA-ACCORD (the US census definition of Latino includes
Brazilians). However, the ethnic heritage of Brazil includes a
large component of African migration, and we performed
subregion analyses which excluded patients initiating ART
in Brazil and patients born in Brazil initiating ART in North
America. We also performed a subregion analysis comparing
NA-ACCORD patients reporting Mexico as their country of
origin with CCASAnet patients from Mexico.
All analyses were performed using R version 3.1.2;
analysis code is available at www.biostat.mc.vanderbilt.edu/
ArchivedAnalyses.
Results
From 2000 to 2011, a total of 11,186 ART-naive Latino
patients initiated ART at one of 19 sites; 8400 (75%) at one of
8 CCASAnet sites in Latin America and 2786 (25%) in one of
11 NA-ACCORD cohorts with clinical sites in 17 US states and
4 Canadian provinces (Figure 1). CCASAnet patients included
2041 initiating ART in Argentina, 1792 in Brazil, 1347 in Chile,
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882 in Honduras, 804 in Mexico and 1534 in Peru. Latinos
initiating ART in North America included 294 with a known
country of birth (156 from Mexico, 40 from other Central
American countries, 69 from South American countries and
29 from the United States); the remaining 2492 patients self-
reported as Latino.





Age, years 35 (29 to 43) 37 (30 to 44) B0.001
Sex B0.001
Female 2268 (27.0%) 550 (19.7%)
Male 6132 (73.0%) 2236 (80.3%)
Route of infection B0.001
Heterosexual 3841 (45.7%) 1040 (37.3%)
MSM 3248 (38.7%) 1313 (47.1%)
IDU 179 (2.1%) 336 (12.0%)
Other 63 (0.8%) 74 (2.7%)
Unknown 1069 (12.7%) 23 (0.9%)
Clinical stage B0.001
AIDS 2443 (29.1%) 605 (21.7%)
Not AIDS 4561 (54.3%) 1735 (62.3%)
Missing 1396 (16.6%) 446 (16.0%)
Nadir CD4 count, cells/mL 148 (54 to 246) 195 (68 to 298) B0.001
Missing 980 (11.7%) 170 (6.1%)
Baseline CD4 count, cells/mL 150 (55 to 253) 212 (79 to 323) B0.001
Missing 1422 (16.9%) 248 (9%)
Baseline viral load (log10) 5.0 (4.5 to 5.4) 4.8 (4.2 to 5.3) B0.001
Missing 2708 (32.2%) 345 (12.4%)
Initial regimen B0.001
NNRTI 6699 (79.8%) 1240 (44.5%)
Boosted PI 1183 (14.1%) 974 (35.0%)
Other 518 (6.2%) 572 (20.5%)
Nucleoside backbone B0.001
ZDV3TC 5604 (66.7%) 597 (21.4%)
TDFFTC 640 (7.6%) 1564 (56.1%)
TDF3TC 562 (6.7%) 127 (4.6%)
D4T3TC 873 (10.4%) 123 (4.4%)
ABC3TC 331 (3.9%) 183 (6.6%)
Other 390 (4.6%) 192 (6.9%)
Regimen anchor B0.001
EFV 5470 (65.1%) 1145 (41.1%)
NVP 1211 (14.4%) 83 (3.0%)
NFV 78 (0.9%) 454 (16.3%)
LPVritonavir 419 (5.0%) 316 (11.3%)
ATVritonavir 279 (3.3%) 454 (16.3%)
Other 943 (11.2%) 517 (18.6%)
Initiation year 2007 (2004 to 2009) 2007 (2003 to 2009) B0.001
VL measurements per person-year 1.95 (1.13 to 2.82) 3.38 (2.50 to 4.41) B0.001
At least one VL measurement B0.001
Yes 7522 (89.5%) 2683 (96.3%)
No 878 (10.5%) 103 (3.7%)
CCASAnet, Caribbean, Central and South America Network for HIV; IDU, injection drug use; MSM, men who have sex with men; NA-ACCORD,
North American AIDS Cohort Collaboration on Research and Design; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor;
VL, viral load. Antiretroviral agents: 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; ATV, atazanavir; D4T, stavudine; EFV, efavirenz; LPV,
lopinavir; NFV, nelfinavir; NVP, nevirapine; TDF, tenofovir; ZDV, zidovudine.
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Demographic and clinical characteristics of patients starting
ART in each cohort are shown in Table 1. Patients initiating
ART in CCASAnet were significantly younger (median 35 vs. 37
years old), more likely to be female (27% vs. 20%) and less
likely to have acquired HIV through injection drug use (2% vs.
12%) than Latinos initiating ART in NA-ACCORD (pB0.001
for all). Median follow-up was 3.3 years (interquartile range
(IQR): 1.2 to 6.0) for patients initiating ART in CCASAnet and
2.7 years (IQR: 1.0 to 5.6) for Latinos in NA-ACCORD.
Crude mortality rates were 2.1 and 1.4 per 100 person-
years for ART initiators in CCASAnet and NA-ACCORD,
respectively. All-cause mortality early after ART initiation
was higher in CCASAnet: 4.4% (95% CI: 4.0 to 4.9%) died
during the first year in CCASAnet compared with 1.5% (95%
CI: 1.0% to 2.0%) in NA-ACCORD (Figure 2). After one year,
the crude mortality rates were 1.28 and 1.33 per 100 person-
years for ART initiators who survived the first year in
CCASAnet and NA-ACCORD, respectively.
In multivariable Cox analyses, CCASAnet patients had a
higher hazard of mortality after ART initiation (adjusted hazard
ratio (AHR) 1.61; 95% CI: 1.32 to 1.96), adjusting for age, sex,
CD4 count, year of ART initiation, intravenous drug use, prior
AIDS diagnosis and ART regimen (Table 2). Among patients
who died in the first year, there was no significant difference
in CD4 count at ART initiation between CCASAnet and NA-
ACCORD (50 vs. 36 cells/mL, p0.35), though CCASAnet
patients were younger (37 vs. 42 years, p0.02) and less
likely to have an AIDS diagnosis before ART initiation (44% vs.
58%, p0.04; Supplementary Table 1).
The cumulative incidence of an ART treatment interrup-
tion, major treatment change, virologic failure and LFU were
lower for CCASAnet participants (Figure 3). The cumulative
incidence of an ART treatment interruption ]14 days was
lower in CCASAnet compared to NA-ACCORD at one year
(0.10 vs. 0.21) and five years (0.21 vs. 0.46). After controlling
for characteristics at ART initiation, the hazard ratio for
treatment interruption was significantly lower for patients in
CCASAnet (AHR: 0.46; 95% CI: 0.42 to 0.50; Table 2).
One and five years after ART initiation, the cumulative
incidence of a regimen change among patients initiating
ART in CCASAnet was 0.07 and 0.23, respectively, and
among Latinos initiating ART in NA-ACCORD, 0.13 and 0.39
(Figure 3b). Similarly, the hazard ratio for changing the initial
regimen was significantly lower for patients in CCASAnet
(AHR: 0.56; 95% CI: 0.51 to 0.62; Table 2). In CCASAnet, 70%
changed from an NNRTI to boosted PI, 24% from one PI to
another PI and 2% to a third-line drug. In NA-ACCORD, 41%
changed from an NNRTI to a boosted PI, 36% from one PI to
another PI and 21% changed to a regimen containing a third-
line drug.
Patients initiating ART in CCASAnet also had a lower
cumulative incidence of virologic failure (AHR 0.52, 95% CI:
0.48 to 0.57; Table 2 and Figure 3c). The results for virologic
failure were not appreciably different when patients were
censored at the start of a treatment interruption ]14 days;
the risk of virologic failure remained lower among CCASAnet
patients (AHR 0.51, 95% CI: 0.45 to 0.56; data not shown).
However, plasma VLwas measured less frequently for patients
in CCASAnet (median of 1.95 measurements per person per
year vs. 3.38 among Latinos in NA-ACCORD). Nonetheless, the
percentage of VL measurements after six months that were
detectable remained lower for patients in CCASAnet (9.6%;
6157/64,043) than for Latinos in NA-ACCORD (19.7%; 6400/
32,423; adjusted relative proportions of 0.53; 95%CI: 0.48
to 0.58).
Lastly, patients initiating ART in CCASAnet had a lower
cumulative incidence of LFU than patients initiating ART
in NA-ACCORD (Figure 3d). One and five years after ART
initiation, the cumulative incidence of LFU among patients
initiating ART in CCASAnet was 0.04 and 0.20, respectively,
and higher among Latinos initiating ART in NA-ACCORD, 0.12
and 0.36.
Subregion analyses
Brazilian CCASAnet sites and Brazilian patients enrolled in NA-
ACCORD were included in the primary analyses, but given the
large component of African migration to Brazil we performed
subregion analyses (Supplementary Table 2) that excluded
patients initiating ART in Brazil (n1792) and patients born
in Brazil initiating ART in North America (n2).The hazard ratio
of death in CCASAnet compared to NA-ACCORD was lower
when Brazilians were excluded (AHR: 1.27; 95% CI: 1.03 to
1.57), whereas there was little difference in the hazard ratios
of treatment interruption, regimen change or virologic failure.
Similarly, the percentage of VL measurements that were
detectable after six months remained lower for patients
initiating ART in CCASAnet in analyses excluding Brazil
(adjusted relative proportion0.52; 95% CI: 0.47 to 0.58).
Among the 804 patients initiating ART in Mexico and 156
Mexicans initiating ART in the United States or Canada, there
was insufficient evidence to suggest a difference in mortality
(AHR: 1.29; 95% CI: 0.43 to 3.85), although the hazard ratio













































Figure 2. Cumulative mortality among Latino patients initiating
ART at Latin American (CCASAnet) and North American (NA-
ACCORD) sites. Time zero represents start of first antiretroviral
therapy regimen. Solid lines indicate 95% confidence intervals
around estimated incidence of mortality.
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initiating ART in Mexico had a lower hazard for virologic
failure (AHR: 0.45; 95% CI: 0.33 to 0.63), although again this
may have been driven by differences in the frequency of
measurements. The percentage of detectable VL measure-
ments was lower among patients initiating ART in Mexico
(adjusted relative proportion0.70; 95% CI: 0.43 to 1.15)
but this difference was not statistically significant.
Discussion
Latinos in the United States and Canada started ART with less
severe immunosuppression and had greater survival, parti-
cularly in the first 12 months of care, as compared with
individuals starting ART in Latin America, but Latinos in
North America also appear to be at greater risk for treatment
interruptions, treatment regimen changes, virologic failure
and LFU.
The lower risk of mortality observed among Latinos in North
America compared to those living in Latin America was most
pronounced in the early years of ART. Early mortality in
resource-limited settings has been well documented, and our
results are largely consistent with other comparisons between
resource-limited settings (primarily sub-Saharan Africa) and
Table 2. Comparison of all-cause mortality, treatment interruption, regimen change and virologic failure between Latinos initiating









NA-ACCORD Ref Ref Ref Ref
CCASAnet 1.61 (1.32 to 1.96) 0.46 (0.42 to 0.50) 0.56 (0.51 to 0.62) 0.52 (0.48 to 0.57)
Sex
Female Ref Ref Ref Ref
Male 1.02 (0.87 to 1.20) 0.75 (0.68 to 0.82) 0.76 (0.69 to 0.82) 0.75 (0.68 to 0.82)
Age
20 0.73 (0.52 to 1.04) 1.47 (1.26 to 1.73) 1.25 (1.06 to 1.47) 1.53(1.30 to 1.80)
30 0.82 (0.71 to 0.95) 1.22 (1.12 to 1.34) 1.09 (1.00 to 1.20) 1.04 (0.95 to 1.14)
40 Ref Ref Ref Ref
50 1.31 (1.20 to 1.43) 0.82 (0.76 to 0.88) 0.98 (0.92 to 1.04) 0.93 (0.87 to 0.99)
60 1.77 (1.42 to 2.20) 0.68 (0.55 to 0.83) 0.99 (0.83 to 1.17) 0.78 (0.65 to 0.94)
Clinical AIDS at baseline
No Ref Ref Ref Ref
Yes 1.27 (1.07 to 1.49) 1.05 (0.94 to 1.17) 1.04 (0.94 to 1.15) 0.94 (0.85 to 1.05)
Baseline CD4 count, cells/mL
50 2.28 (1.80 to 2.88) 0.88 (0.78 to 0.99) 1.32 (1.17 to 1.49) 1.05 (0.93 to 1.18)
100 1.68 (1.34 to 2.10) 0.85 (0.76 to 0.95) 1.22 (1.08 to 1.36) 1.00 (0.90 to 1.13)
200 1.09 (0.93 to 1.28) 0.90 (0.84 to 0.95) 1.05 (0.98 to 1.13) 0.90 (0.85 to 0.97)
350 Ref Ref Ref
Initiation year
2000 0.82 (0.62 to 1.09) 1.33 (1.16 to 1.54) 0.86 (0.74 to 1.01) 1.88 (1.62 to 2.18)
2002 0.92 (0.79 to 1.07) 1.25 (1.15 to 1.35) 0.86 (0.79 to 0.94) 1.56 (1.44 to 1.70)
2004 1.00 (0.90 to 1.11) 1.15 (1.08 to 1.22) 0.89 (0.84 to 0.94) 1.27 (1.20 to 1.36)
2006 Ref Ref Ref Ref
2008 0.97 (0.85 to 1.10) 0.85 (0.79 to 0.91) 1.29 (1.20 to 1.38) 0.85 (0.79 to 0.92)
2010 1.02 (0.82 to 1.27) 0.74 (0.65 to 0.84) 1.93 (1.71 to 2.17) 0.95 (0.83 to 1.10)
ART regimen class
NNRTI Ref Ref Ref Ref
PI 0.93 (0.77 to 1.13) 1.18 (1.06 to 1.31) 1.05 (0.95 to 1.17) 1.38 (1.24 to 1.53)
Other 1.27 (1.00 to 1.60) 1.50 (1.34 to 1.69) 1.73 (1.53 to 1.94) 1.70 (1.50 to 1.91)
History of IDU
No Ref Ref Ref Ref
Yes 1.64 (1.21 to 2.21) 1.42 (1.22 to 1.65) 1.28 (1.08 to 1.51) 1.71 (1.46 to 2.01)
Estimates presented as hazard ratio (95% confidence interval). CCASAnet, Caribbean, Central and South America Network for HIV; IDU, injection
drug use; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design; NNRTI, non-nucleoside reverse transcriptase
inhibitor; Ref, reference category; PI, protease inhibitor. Continuous variables were modelled using restricted cubic splines, and the hazard ratios
and confidence intervals shown for age, baseline CD4 count, and year of ART initiation represent predicted values estimated from the model.
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North America and Europe [21]. Patients initiating ART in Latin
America had a greater degree of immunosuppression.
Although cause of death was not available, other studies
have reported AIDS-related conditions as the leading cause of
early mortality after treatment initiation in Latin America, and
this predominance has not changed despite the improved
survival observed in the era of modern combination ART
regimens [2225].
Compared to non-Hispanic whites, Latinos in the United
States as a group are diagnosed at a more advanced HIV
disease, and foreign-born, non-English speaking and male
Latinos are at particularly high risk of delayed diagnosis
[2632]. Barriers to engagement in HIV care in the United
States may be greater for Latinos than other ethnic groups.
An analysis of 2010 data found that among Hispanics or
Latinos diagnosed with HIV, rates at all stages of the care
continuum were lower than among non-Hispanic whites [3].
A recent study of a predominantly Hispanic HIV cohort in
Texas, found that 46% of patients lacked insurance and an
additional 14% were receiving Medicaid [5]. There can also
be particular challenges for Latinos due to linguistic bar-
riers and differences in patient-provider communication.






































































































(c) (d) Loss to follow-up
Figure 3. Cumulative incidence of antiretroviral therapy (ART) treatment interruption, ART regimen change, virologic failure and loss to
follow-up among CCASAnet and Latino NA-ACCORD patients. All panels show the cumulative incidence of each outcome among CCASAnet
and NA-ACCORD patients using a competing risks model where time zero represents the start of the first ART regimen. Solid lines indicate
95% confidence intervals around estimated incidence of treatment interruption. (a) Cumulative incidence of a 14-day or greater ART
treatment interruption; (b) cumulative incidence of a change from the initial treatment to a second-line regimen; (c) cumulative incidence of
virologic failure among patients who had at least one viral load measurement after treatment initiation; (d) cumulative incidence of loss to
follow-up.
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For example, prior studies have identified less patient-
centred and psychosocial language use by HIV clinicians
treating Hispanics versus non-Hispanics [68].
Prior studies have also identified important differences
among native and foreign-born Latinos in the United States,
which may be representative of broader geographic trends.
Studies from the United States found that foreign-born
Latino males are more likely to have acquired HIV through
heterosexual contact as compared to US-born Latinos.
Among HIV-positive Latinas, foreign-born women were older
at first sexual contact, had fewer episodes of non-HIV
sexually transmitted diseases and lower rates of drug and
alcohol abuse [27,33,34].
We examined health outcomes at CCASAnet sites in
aggregate, but prior studies have found that mortality and
programme retention vary considerably between countries in
Latin America, which likely reflects differences in the under-
lying demographics of the HIV epidemic in the region, as well
as local social and economic characteristics [9,1113,35,36].
Heterogeneity in mortality could be related to different
programme retention and death ascertainment. Rates of
treatment change also vary by CCASAnet sites, with geo-
graphic differences in specific toxicities as well as uneven
availability of second- and third-line medications, which may
be a source of possible confounding [37,38]. The cumulative
incidence of regimen change in NA-ACCORD was higher than
in CCASAnet, and 21% of patients changing regimens switched
to a third-line agent in NA-ACCORD, compared to 2% in
CCASAnet.This figuremay reflect a greater availability of third-
line agents driving a higher cumulative incidence of regimen
change, particularly if the change occurs for tolerability issues
(which might not be an option in CCASAnet countries with a
more limited ART selection). However, it should be noted that
cumulative incidence of virologic failure was also higher in NA-
ACCORD, so the greater utilization of third-line agents may
simply reflect a greater burden of HIV drug resistance.
A strength of this study was the large number of subjects
contributing data from multiple countries. However, the
largest number of North American Latino patients with
known foreign birth location had migrated from Mexico,
whereas the majority of CCASAnet patients were located in
South America. Limitations of our data included the pro-
portion of patients with no reported country of birth in NA-
ACCORD. Other limitations included the lack of information
on causes of death and potential confounding of the
treatment interruption analysis related to how accurately
sites record gaps in ART use (i.e. adherence) versus gaps in
prescriptions for ART. Although we assessed time to virologic
failure, we did not assess the role of adherence and viral
resistance in treatment failure, nor toxicity or other reasons
for ART change.
Conclusions
Mortality rates were higher in Latin America, possibly due to
treatment initiation at more advanced stages of HIV disease,
whereas treatment interruption, major regimen modification,
virologic failure and LFU were higher in North America,
where barriers to receiving quality HIV care may be higher for
Latino populations. These results emphasize once again the
need for early diagnosis and treatment initiation in Latin
America and reinforce the key role of ensuring US Latino HIV
patients have consistent access to care to improve treatment
outcomes.
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